NanoViricides Launches Phase II Trial for Monkeypox Antiviral Drug in DRC
- Reports
- 6
- Developments
- 1
- Repetition
- 83%
New informationRepeats or wire copies
What happened
NanoViricides, Inc. announced the commencement of a Phase II clinical trial for its novel broad-spectrum antiviral drug, NV-387, intended for Monkeypox Virus Infection. The trial is being conducted in the Democratic Republic of the Congo and is registered in the Pan African Clinical Trials Registry database. The study, which is entitled 'An adaptive international, multi-center, randomized, open-label, interventional, parallel group, phase II (IIa and IIb) clinical trial,' evaluates the efficacy and safety of NV-387, formulated as oral gummies, against standard of care.
From tennesseedaily.com
Why it matters
The trial is led by Prof. Vivi Maketa Tevuzula, a Professor in the Department of Tropical Medicine at the University of Kinshasa and Principal Investigator at IMABE in Kinshasa. The successful completion of this trial could establish a new treatment avenue for Monkeypox and contribute to global health security goals.
From tennesseedaily.com
Who's involved
- DRCCompany conducting the clinical trial of the antiviral drug NV-387.
- KinshasaHost city for the clinical trial and home of the Principal Investigator.
- Democratic Republic of the CongoCountry hosting the clinical trial for the antiviral drug.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Democratic Republic of the CongoSpeculative
The country could attract foreign health investment by successfully hosting advanced clinical trials.